Exploration
Accueil
Racine
Exploration
Accueil

Corpus GrippeCanadaV3

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

An incremental economic evaluation of targeted and universal influenza vaccination in pregnant women.

Identifieur interne : 000C86 ( Main/Exploration ); précédent : 000C85; suivant : 000C87

An incremental economic evaluation of targeted and universal influenza vaccination in pregnant women.

Auteurs : Chris Skedgel [Canada] ; Joanne M. Langley ; Noni E. Macdonald ; Jeff Scott ; Shelly Mcneil

Source :

RBID : pubmed:22164556

Descripteurs français

English descriptors

Abstract

OBJECTIVE

Pregnancy is associated with increased influenza hospitalizations and physician visits (events) in healthy women and those with co-morbidities. Annual influenza immunization is recommended for all pregnant women. Although vaccination is expected to reduce influenza-related events, the economic implications are unclear. We developed an economic model to estimate the cost-effectiveness (CE) of different vaccination strategies in Nova Scotia.

METHODS

A decision tree characterized the one-year costs and consequences of targeted (pregnant women with co-morbidities only) and universal (all pregnant women) vaccination strategies relative to a no-vaccination strategy. Baseline event probabilities, vaccine effectiveness, costs and quality-of-life weights were derived from individual-level Nova Scotia administrative databases, health system sources and published reports. Sensitivity analyses tested the impact of varying key parameters, including vaccine effectiveness and mode of delivery.

RESULTS

Targeted vaccination was cost-saving relative to no vaccination when delivered by public health clinics (PHC) or routine family practitioner (FP) visit. Cost per quality-adjusted life year gained by universal vaccination relative to targeted strategy was < $40,000 when delivered by PHC or routine FP visit. Net cost of universal vaccination by PHC or a routine FP visit was < $10 per pregnant woman.

CONCLUSION

Universal vaccination of pregnant women appears cost-effective when delivered by PHC or as part of a routine FP prenatal visit. Targeted vaccination of pregnant women with co-morbidities can be cost-saving, but the possibility of higher vaccine uptake with a universal compared to a targeted strategy must be considered in addition to costs in program planning.


PubMed: 22164556


Affiliations:

Links toward previous steps (curation, corpus...)

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">An incremental economic evaluation of targeted and universal influenza vaccination in pregnant women.</title>
<author>
<name sortKey="Skedgel, Chris" sort="Skedgel, Chris" uniqKey="Skedgel C" first="Chris" last="Skedgel">Chris Skedgel</name>
<affiliation wicri:level="1">
<nlm:affiliation>Canadian Center for Vaccinology, IWK Health Centre, Capital District Health Authority and Dalhousie University, Halifax, NS. chris.skedgel@cdha.nshealth.ca</nlm:affiliation>
<country wicri:rule="url">Canada</country>
</affiliation>
</author>
<author>
<name sortKey="Langley, Joanne M" sort="Langley, Joanne M" uniqKey="Langley J" first="Joanne M" last="Langley">Joanne M. Langley</name>
</author>
<author>
<name sortKey="Macdonald, Noni E" sort="Macdonald, Noni E" uniqKey="Macdonald N" first="Noni E" last="Macdonald">Noni E. Macdonald</name>
</author>
<author>
<name sortKey="Scott, Jeff" sort="Scott, Jeff" uniqKey="Scott J" first="Jeff" last="Scott">Jeff Scott</name>
</author>
<author>
<name sortKey="Mcneil, Shelly" sort="Mcneil, Shelly" uniqKey="Mcneil S" first="Shelly" last="Mcneil">Shelly Mcneil</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="????">
<PubDate>
<MedlineDate>2011 Nov-Dec</MedlineDate>
</PubDate>
</date>
<idno type="RBID">pubmed:22164556</idno>
<idno type="pmid">22164556</idno>
<idno type="wicri:Area/Main/Corpus">000471</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000471</idno>
<idno type="wicri:Area/Main/Curation">000471</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000471</idno>
<idno type="wicri:Area/Main/Exploration">000471</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">An incremental economic evaluation of targeted and universal influenza vaccination in pregnant women.</title>
<author>
<name sortKey="Skedgel, Chris" sort="Skedgel, Chris" uniqKey="Skedgel C" first="Chris" last="Skedgel">Chris Skedgel</name>
<affiliation wicri:level="1">
<nlm:affiliation>Canadian Center for Vaccinology, IWK Health Centre, Capital District Health Authority and Dalhousie University, Halifax, NS. chris.skedgel@cdha.nshealth.ca</nlm:affiliation>
<country wicri:rule="url">Canada</country>
</affiliation>
</author>
<author>
<name sortKey="Langley, Joanne M" sort="Langley, Joanne M" uniqKey="Langley J" first="Joanne M" last="Langley">Joanne M. Langley</name>
</author>
<author>
<name sortKey="Macdonald, Noni E" sort="Macdonald, Noni E" uniqKey="Macdonald N" first="Noni E" last="Macdonald">Noni E. Macdonald</name>
</author>
<author>
<name sortKey="Scott, Jeff" sort="Scott, Jeff" uniqKey="Scott J" first="Jeff" last="Scott">Jeff Scott</name>
</author>
<author>
<name sortKey="Mcneil, Shelly" sort="Mcneil, Shelly" uniqKey="Mcneil S" first="Shelly" last="Mcneil">Shelly Mcneil</name>
</author>
</analytic>
<series>
<title level="j">Canadian journal of public health = Revue canadienne de sante publique</title>
<idno type="ISSN">0008-4263</idno>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Comorbidity</term>
<term>Cost-Benefit Analysis</term>
<term>Female</term>
<term>Humans</term>
<term>Influenza Vaccines (administration & dosage)</term>
<term>Influenza Vaccines (economics)</term>
<term>Influenza, Human (economics)</term>
<term>Influenza, Human (immunology)</term>
<term>Influenza, Human (prevention & control)</term>
<term>Models, Economic</term>
<term>Nova Scotia</term>
<term>Pregnancy</term>
<term>Pregnancy Complications, Infectious (economics)</term>
<term>Pregnancy Complications, Infectious (immunology)</term>
<term>Pregnancy Complications, Infectious (prevention & control)</term>
<term>Pregnant Women</term>
<term>Quality-Adjusted Life Years</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Analyse coût-bénéfice</term>
<term>Années de vie ajustées sur la qualité</term>
<term>Comorbidité</term>
<term>Complications de la grossesse et maladies infectieuses ()</term>
<term>Complications de la grossesse et maladies infectieuses (immunologie)</term>
<term>Complications de la grossesse et maladies infectieuses (économie)</term>
<term>Femelle</term>
<term>Femmes enceintes</term>
<term>Grippe humaine ()</term>
<term>Grippe humaine (immunologie)</term>
<term>Grippe humaine (économie)</term>
<term>Grossesse</term>
<term>Humains</term>
<term>Modèles économiques</term>
<term>Nouvelle-Écosse</term>
<term>Vaccins antigrippaux (administration et posologie)</term>
<term>Vaccins antigrippaux (économie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en">
<term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en">
<term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en">
<term>Nova Scotia</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr">
<term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="economics" xml:lang="en">
<term>Influenza, Human</term>
<term>Pregnancy Complications, Infectious</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr">
<term>Complications de la grossesse et maladies infectieuses</term>
<term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en">
<term>Influenza, Human</term>
<term>Pregnancy Complications, Infectious</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en">
<term>Influenza, Human</term>
<term>Pregnancy Complications, Infectious</term>
</keywords>
<keywords scheme="MESH" qualifier="économie" xml:lang="fr">
<term>Complications de la grossesse et maladies infectieuses</term>
<term>Grippe humaine</term>
<term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Comorbidity</term>
<term>Cost-Benefit Analysis</term>
<term>Female</term>
<term>Humans</term>
<term>Models, Economic</term>
<term>Pregnancy</term>
<term>Pregnant Women</term>
<term>Quality-Adjusted Life Years</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Analyse coût-bénéfice</term>
<term>Années de vie ajustées sur la qualité</term>
<term>Comorbidité</term>
<term>Complications de la grossesse et maladies infectieuses</term>
<term>Femelle</term>
<term>Femmes enceintes</term>
<term>Grippe humaine</term>
<term>Grossesse</term>
<term>Humains</term>
<term>Modèles économiques</term>
<term>Nouvelle-Écosse</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">
<p>
<b>OBJECTIVE</b>
</p>
<p>Pregnancy is associated with increased influenza hospitalizations and physician visits (events) in healthy women and those with co-morbidities. Annual influenza immunization is recommended for all pregnant women. Although vaccination is expected to reduce influenza-related events, the economic implications are unclear. We developed an economic model to estimate the cost-effectiveness (CE) of different vaccination strategies in Nova Scotia.</p>
</div>
<div type="abstract" xml:lang="en">
<p>
<b>METHODS</b>
</p>
<p>A decision tree characterized the one-year costs and consequences of targeted (pregnant women with co-morbidities only) and universal (all pregnant women) vaccination strategies relative to a no-vaccination strategy. Baseline event probabilities, vaccine effectiveness, costs and quality-of-life weights were derived from individual-level Nova Scotia administrative databases, health system sources and published reports. Sensitivity analyses tested the impact of varying key parameters, including vaccine effectiveness and mode of delivery.</p>
</div>
<div type="abstract" xml:lang="en">
<p>
<b>RESULTS</b>
</p>
<p>Targeted vaccination was cost-saving relative to no vaccination when delivered by public health clinics (PHC) or routine family practitioner (FP) visit. Cost per quality-adjusted life year gained by universal vaccination relative to targeted strategy was < $40,000 when delivered by PHC or routine FP visit. Net cost of universal vaccination by PHC or a routine FP visit was < $10 per pregnant woman.</p>
</div>
<div type="abstract" xml:lang="en">
<p>
<b>CONCLUSION</b>
</p>
<p>Universal vaccination of pregnant women appears cost-effective when delivered by PHC or as part of a routine FP prenatal visit. Targeted vaccination of pregnant women with co-morbidities can be cost-saving, but the possibility of higher vaccine uptake with a universal compared to a targeted strategy must be considered in addition to costs in program planning.</p>
</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">22164556</PMID>
<DateCompleted>
<Year>2012</Year>
<Month>01</Month>
<Day>10</Day>
</DateCompleted>
<DateRevised>
<Year>2020</Year>
<Month>02</Month>
<Day>05</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0008-4263</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>102</Volume>
<Issue>6</Issue>
<PubDate>
<MedlineDate>2011 Nov-Dec</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Canadian journal of public health = Revue canadienne de sante publique</Title>
<ISOAbbreviation>Can J Public Health</ISOAbbreviation>
</Journal>
<ArticleTitle>An incremental economic evaluation of targeted and universal influenza vaccination in pregnant women.</ArticleTitle>
<Pagination>
<MedlinePgn>445-50</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Pregnancy is associated with increased influenza hospitalizations and physician visits (events) in healthy women and those with co-morbidities. Annual influenza immunization is recommended for all pregnant women. Although vaccination is expected to reduce influenza-related events, the economic implications are unclear. We developed an economic model to estimate the cost-effectiveness (CE) of different vaccination strategies in Nova Scotia.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">A decision tree characterized the one-year costs and consequences of targeted (pregnant women with co-morbidities only) and universal (all pregnant women) vaccination strategies relative to a no-vaccination strategy. Baseline event probabilities, vaccine effectiveness, costs and quality-of-life weights were derived from individual-level Nova Scotia administrative databases, health system sources and published reports. Sensitivity analyses tested the impact of varying key parameters, including vaccine effectiveness and mode of delivery.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Targeted vaccination was cost-saving relative to no vaccination when delivered by public health clinics (PHC) or routine family practitioner (FP) visit. Cost per quality-adjusted life year gained by universal vaccination relative to targeted strategy was < $40,000 when delivered by PHC or routine FP visit. Net cost of universal vaccination by PHC or a routine FP visit was < $10 per pregnant woman.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Universal vaccination of pregnant women appears cost-effective when delivered by PHC or as part of a routine FP prenatal visit. Targeted vaccination of pregnant women with co-morbidities can be cost-saving, but the possibility of higher vaccine uptake with a universal compared to a targeted strategy must be considered in addition to costs in program planning.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Skedgel</LastName>
<ForeName>Chris</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Canadian Center for Vaccinology, IWK Health Centre, Capital District Health Authority and Dalhousie University, Halifax, NS. chris.skedgel@cdha.nshealth.ca</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Langley</LastName>
<ForeName>Joanne M</ForeName>
<Initials>JM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>MacDonald</LastName>
<ForeName>Noni E</ForeName>
<Initials>NE</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Scott</LastName>
<ForeName>Jeff</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>McNeil</LastName>
<ForeName>Shelly</ForeName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Switzerland</Country>
<MedlineTA>Can J Public Health</MedlineTA>
<NlmUniqueID>0372714</NlmUniqueID>
<ISSNLinking>0008-4263</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018803" MajorTopicYN="N">Models, Economic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D009674" MajorTopicYN="N" Type="Geographic">Nova Scotia</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011251" MajorTopicYN="N">Pregnancy Complications, Infectious</DescriptorName>
<QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D037841" MajorTopicYN="Y">Pregnant Women</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D019057" MajorTopicYN="N">Quality-Adjusted Life Years</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2011</Year>
<Month>12</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2011</Year>
<Month>12</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2012</Year>
<Month>1</Month>
<Day>11</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">22164556</ArticleId>
<ArticleId IdType="pmc">PMC6973660</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>J Obstet Gynaecol Can. 2007 Aug;29(8):622-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17714614</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Obstet Gynecol. 2005 Apr;192(4):1098-106</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15846187</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Infect Dis. 2009 Dec 15;49(12):1784-92</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19911967</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Stat Methods Med Res. 2002 Dec;11(6):455-68</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12516984</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Infect Dis. 1997 Dec;176 Suppl 2:S92-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9396689</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Health Econ. 1999 Jun;18(3):341-64</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10537899</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Health Rep. 2003 Aug;14(4):41-53</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14608795</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Can J Public Health. 2009 Sep-Oct;100(5):340-3</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19994733</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Obstet Gynaecol Can. 2007 Aug;29(8):674-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17714623</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Epidemiol. 1980 Dec;112(6):798-811</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7457471</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cochrane Database Syst Rev. 2004;(3):CD001269</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15266445</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Epidemiol. 1998 Dec 1;148(11):1094-102</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9850132</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet Infect Dis. 2008 Jan;8(1):44-52</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18156088</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>CMAJ. 2007 Feb 13;176(4):463-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17296958</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Infect Dis. 2010 Dec 15;51(12):1355-61</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21058908</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet Infect Dis. 2010 Sep;10(9):643-51</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20797646</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Obstet Gynecol. 2006 Jun;107(6):1323-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16738159</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Value Health. 2003 Mar-Apr;6(2):116-25</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12641862</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Can Commun Dis Rep. 2007 Nov 1;33(11):23-4</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18163241</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>MMWR Recomm Rep. 2009 Jul 31;58(RR-8):1-52</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19644442</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2008 Oct 9;359(15):1555-64</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18799552</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>Canada</li>
</country>
</list>
<tree>
<noCountry>
<name sortKey="Langley, Joanne M" sort="Langley, Joanne M" uniqKey="Langley J" first="Joanne M" last="Langley">Joanne M. Langley</name>
<name sortKey="Macdonald, Noni E" sort="Macdonald, Noni E" uniqKey="Macdonald N" first="Noni E" last="Macdonald">Noni E. Macdonald</name>
<name sortKey="Mcneil, Shelly" sort="Mcneil, Shelly" uniqKey="Mcneil S" first="Shelly" last="Mcneil">Shelly Mcneil</name>
<name sortKey="Scott, Jeff" sort="Scott, Jeff" uniqKey="Scott J" first="Jeff" last="Scott">Jeff Scott</name>
</noCountry>
<country name="Canada">
<noRegion>
<name sortKey="Skedgel, Chris" sort="Skedgel, Chris" uniqKey="Skedgel C" first="Chris" last="Skedgel">Chris Skedgel</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeCanadaV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C86 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000C86 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    GrippeCanadaV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:22164556
   |texte=   An incremental economic evaluation of targeted and universal influenza vaccination in pregnant women.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:22164556" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a GrippeCanadaV3
Wicri

This area was generated with Dilib version V0.6.35.
Data generation: Tue Jul 7 13:36:58 2020. Site generation: Sat Sep 26 07:06:42 2020